25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

LIPO (Lipella) Stock Analysis
Buy, Hold or Sell?

Let's analyze Lipella together

I guess you are interested in Lipella Pharmaceuticals Inc. Common Stock. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • ๐Ÿ“Š Fundamental Analysis (FA) โ€“ Lipellaโ€™s Financial Insights
  • ๐Ÿ“ˆ Technical Analysis (TA) โ€“ Lipellaโ€™s Price Targets

I'm going to help you getting a better view of Lipella Pharmaceuticals Inc. Common Stock. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Lipella Pharmaceuticals Inc. Common Stock

I send you an email if I find something interesting about Lipella Pharmaceuticals Inc. Common Stock.

1. Quick Overview

1.1. Quick analysis of Lipella (30 sec.)










1.2. What can you expect buying and holding a share of Lipella? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$0.91
Expected worth in 1 year
$1.25
How sure are you?
31.3%

+ What do you gain per year?

Total Gains per Share
$0.34
Return On Investment
59.6%

For what price can you sell your share?

Current Price per Share
$0.57
Expected price per share
$0.55 - $0.641
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Lipella (5 min.)




Live pricePrice per Share (EOD)
$0.57
Intrinsic Value Per Share
$-15,672.90 - $-18,837.03
Total Value Per Share
$-15,671.99 - $-18,836.12

2.2. Growth of Lipella (5 min.)




Is Lipella growing?

Current yearPrevious yearGrowGrow %
How rich?$4m$2.7m-$472.8k-20.6%

How much money is Lipella making?

Current yearPrevious yearGrowGrow %
Making money-$327.5m-$1.1m-$326.4m-99.6%
Net Profit Margin-1,081.2%-347.4%--

How much money comes from the company's main activities?

2.3. Financial Health of Lipella (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Lipella?

Welcome investor! Lipella's management wants to use your money to grow the business. In return you get a share of Lipella.

First you should know what it really means to hold a share of Lipella. And how you can make/lose money.

Speculation

The Price per Share of Lipella is $0.57. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Lipella.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Lipella, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.91. Based on the TTM, the Book Value Change Per Share is $0.08 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.07 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Lipella.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-292.46-51,308.3%-73.33-12,864.6%-0.27-46.6%-24.59-4,313.3%-18.47-3,240.1%-18.47-3,240.1%
Usd Book Value Change Per Share0.4884.8%0.0814.9%-0.07-12.3%0.0610.3%0.0610.0%0.0610.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.4884.8%0.0814.9%-0.07-12.3%0.0610.3%0.0610.0%0.0610.0%
Usd Price Per Share2.51-1.62-1.34-1.41-1.06-1.06-
Price to Earnings Ratio0.00--0.82--1.28--1.67--1.25--1.25-
Price-to-Total Gains Ratio5.19-5.96--5.39--0.49--0.49--0.49-
Price to Book Ratio2.75-3.12-2.18-2.21-1.65-1.65-
Price-to-Total Gains Ratio5.19-5.96--5.39--0.49--0.49--0.49-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.57
Number of shares1754
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.080.06
Usd Total Gains Per Share0.080.06
Gains per Quarter (1754 shares)148.99100.10
Gains per Year (1754 shares)595.97400.40
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
105965860400390
20119211820801790
3017881778012011190
4023842374016021590
5029802970020021990
6035763566024022390
7041724162028032790
8047684758032033190
9053645354036043590
10059605950040043990

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.016.00.00.0%0.016.00.00.0%0.016.00.00.0%
Book Value Change Per Share2.02.00.050.0%4.08.00.033.3%5.09.02.031.3%5.09.02.031.3%5.09.02.031.3%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.016.00.0%0.00.016.00.0%0.00.016.00.0%
Total Gains per Share2.02.00.050.0%4.08.00.033.3%5.09.02.031.3%5.09.02.031.3%5.09.02.031.3%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Lipella Pharmaceuticals Inc. Common Stock compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.4830.085+469%-0.070+115%0.059+721%0.057+747%0.057+747%
Book Value Per Share--0.9130.513+78%0.619+48%0.541+69%0.438+108%0.438+108%
Current Ratio--6.2094.244+46%7.623-19%5.128+21%4.418+41%4.418+41%
Debt To Asset Ratio--0.1600.247-35%0.157+2%0.311-49%0.276-42%0.276-42%
Debt To Equity Ratio--0.1900.337-43%0.189+1%0.381-50%0.352-46%0.352-46%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--14661339.0008798759.200+67%8202192.250+79%9776578.980+50%9776578.980+50%9776578.980+50%
Eps---292.457-73.328-75%-0.265-100%-24.586-92%-18.468-94%-18.468-94%
Ev To Ebitda Ratio---0.003-0.955+33924%-1.817+64684%-2.630+93663%-2.630+93663%-2.630+93663%
Ev To Sales Ratio--0.0288.817-100%5.815-100%11.332-100%11.332-100%11.332-100%
Free Cash Flow Per Share---319.230-79.951-75%-1.002-100%-27.025-92%-20.291-94%-20.291-94%
Free Cash Flow To Equity Per Share--456.675114.173+300%-0.914+100%37.809+1108%28.365+1510%28.365+1510%
Gross Profit Margin--1.00086.248-99%892.072-100%326.440-100%245.080-100%245.080-100%
Intrinsic Value_10Y_max---18837.030----------
Intrinsic Value_10Y_min---15672.905----------
Intrinsic Value_1Y_max---366.198----------
Intrinsic Value_1Y_min---358.801----------
Intrinsic Value_3Y_max---2259.763----------
Intrinsic Value_3Y_min---2133.949----------
Intrinsic Value_5Y_max---5551.228----------
Intrinsic Value_5Y_min---5052.711----------
Market Cap2546418.000-340%11213174.0007239421.700+55%5969563.250+88%6294194.317+78%4720645.738+138%4720645.738+138%
Net Profit Margin---10.098-10.812+7%-3.474-66%-5.716-43%-7.205-29%-7.205-29%
Operating Margin---10.098-10.812+7%-3.478-66%-5.925-41%-8.088-20%-8.088-20%
Operating Ratio--11.27010.412+8%4.106+175%6.150+83%10.424+8%10.424+8%
Pb Ratio0.624-340%2.7493.118-12%2.180+26%2.205+25%1.654+66%1.654+66%
Pe Ratio0.000+77%-0.002-0.816+37949%-1.279+59494%-1.669+77676%-1.252+58232%-1.252+58232%
Price Per Share0.570-340%2.5101.621+55%1.336+88%1.409+78%1.057+138%1.057+138%
Price To Free Cash Flow Ratio0.000+77%-0.002-1.199+60890%-1.664+84539%-2.381+121009%-1.785+90732%-1.785+90732%
Price To Total Gains Ratio1.179-340%5.1925.956-13%-5.390+204%-0.492+109%-0.492+109%-0.492+109%
Quick Ratio--5.549485.445-99%6.893-20%165.053-97%124.451-96%124.451-96%
Return On Assets---269.051-67.672-75%-0.370-100%-22.835-92%-17.169-94%-17.169-94%
Return On Equity---320.289-80.645-75%-0.443-100%-27.244-91%-20.629-94%-20.629-94%
Total Gains Per Share--0.4830.085+469%-0.070+115%0.059+721%0.057+747%0.057+747%
Usd Book Value--4079204.0002290343.250+78%2763200.000+48%2416295.833+69%1958740.750+108%1958740.750+108%
Usd Book Value Change Per Share--0.4830.085+469%-0.070+115%0.059+721%0.057+747%0.057+747%
Usd Book Value Per Share--0.9130.513+78%0.619+48%0.541+69%0.438+108%0.438+108%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--14661339.0008798759.200+67%8202192.250+79%9776578.980+50%9776578.980+50%9776578.980+50%
Usd Eps---292.457-73.328-75%-0.265-100%-24.586-92%-18.468-94%-18.468-94%
Usd Free Cash Flow---1426126000.000-357172077.000-75%-4474242.250-100%-120732916.667-92%-90645798.813-94%-90645798.813-94%
Usd Free Cash Flow Per Share---319.230-79.951-75%-1.002-100%-27.025-92%-20.291-94%-20.291-94%
Usd Free Cash Flow To Equity Per Share--456.675114.173+300%-0.914+100%37.809+1108%28.365+1510%28.365+1510%
Usd Market Cap2546418.000-340%11213174.0007239421.700+55%5969563.250+88%6294194.317+78%4720645.738+138%4720645.738+138%
Usd Price Per Share0.570-340%2.5101.621+55%1.336+88%1.409+78%1.057+138%1.057+138%
Usd Profit---1306523000.000-327586863.750-75%-1185737.250-100%-109834631.500-92%-82505877.938-94%-82505877.938-94%
Usd Revenue--129390000.00032445119.250+299%52748430.500+145%28420271.167+355%21333484.375+507%21333484.375+507%
Usd Total Gains Per Share--0.4830.085+469%-0.070+115%0.059+721%0.057+747%0.057+747%
 EOD+2 -6MRQTTM+22 -16YOY+17 -213Y+20 -185Y+20 -1810Y+20 -18

3.3 Fundamental Score

Let's check the fundamental score of Lipella Pharmaceuticals Inc. Common Stock based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-150.000
Price to Book Ratio (EOD)Between0-10.624
Net Profit Margin (MRQ)Greater than0-10.098
Operating Margin (MRQ)Greater than0-10.098
Quick Ratio (MRQ)Greater than15.549
Current Ratio (MRQ)Greater than16.209
Debt to Asset Ratio (MRQ)Less than10.160
Debt to Equity Ratio (MRQ)Less than10.190
Return on Equity (MRQ)Greater than0.15-320.289
Return on Assets (MRQ)Greater than0.05-269.051
Total5/10 (50.0%)

3.4 Technical Score

Let's check the technical score of Lipella Pharmaceuticals Inc. Common Stock based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose0.591
Total1/1 (100.0%)

4. In-depth Analysis

4.1 About Lipella Pharmaceuticals Inc. Common Stock

Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It develops LP-10, a formulation of tacrolimus for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; LP-410, an oral liposomal formulation of tacrolimus to treat oral graft-versus-host disease; and LP-50, an intravesical formulation of immunoglobulins for the treatment of non-muscle invasive bladder cancer. Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.

Fundamental data was last updated by Penke on 2025-08-16 20:39:04.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitย Lipella earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareย Lipella to theย Biotechnology industry mean.
  • A Net Profit Margin of -1,009.8%ย means thatย $-10.10 for each $1ย in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Lipella Pharmaceuticals Inc. Common Stock:

  • The MRQ is -1,009.8%. The company is making a huge loss. -2
  • The TTM is -1,081.2%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-1,009.8%TTM-1,081.2%+71.4%
TTM-1,081.2%YOY-347.4%-733.8%
TTM-1,081.2%5Y-720.5%-360.7%
5Y-720.5%10Y-720.5%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1,009.8%-91.7%-918.1%
TTM-1,081.2%-160.2%-921.0%
YOY-347.4%-209.8%-137.6%
3Y-571.6%-278.1%-293.5%
5Y-720.5%-362.4%-358.1%
10Y-720.5%-517.9%-202.6%
4.3.1.2. Return on Assets

Shows howย efficientย Lipella is using its assets to generate profit.

  • Above 5% is considered healthyย but always compareย Lipella to theย Biotechnology industry mean.
  • -26,905.1% Return on Assets means thatย Lipella generatedย $-269.05 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Lipella Pharmaceuticals Inc. Common Stock:

  • The MRQ is -26,905.1%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -6,767.2%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-26,905.1%TTM-6,767.2%-20,137.9%
TTM-6,767.2%YOY-37.0%-6,730.2%
TTM-6,767.2%5Y-1,716.9%-5,050.3%
5Y-1,716.9%10Y-1,716.9%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-26,905.1%-12.0%-26,893.1%
TTM-6,767.2%-11.9%-6,755.3%
YOY-37.0%-11.2%-25.8%
3Y-2,283.5%-11.9%-2,271.6%
5Y-1,716.9%-11.6%-1,705.3%
10Y-1,716.9%-13.6%-1,703.3%
4.3.1.3. Return on Equity

Shows how efficient Lipella is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareย Lipella to theย Biotechnology industry mean.
  • -32,028.9% Return on Equity means Lipella generated $-320.29ย for eachย $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Lipella Pharmaceuticals Inc. Common Stock:

  • The MRQ is -32,028.9%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -8,064.5%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-32,028.9%TTM-8,064.5%-23,964.4%
TTM-8,064.5%YOY-44.3%-8,020.2%
TTM-8,064.5%5Y-2,062.9%-6,001.6%
5Y-2,062.9%10Y-2,062.9%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-32,028.9%-14.2%-32,014.7%
TTM-8,064.5%-14.7%-8,049.8%
YOY-44.3%-15.0%-29.3%
3Y-2,724.4%-16.5%-2,707.9%
5Y-2,062.9%-17.0%-2,045.9%
10Y-2,062.9%-19.2%-2,043.7%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Lipella Pharmaceuticals Inc. Common Stock.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measuresย how efficient Lipella is operatingย .

  • Measures how much profit Lipella makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareย Lipella to theย Biotechnology industry mean.
  • An Operating Margin of -1,009.8%ย means the company generated $-10.10 ย for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Lipella Pharmaceuticals Inc. Common Stock:

  • The MRQ is -1,009.8%. The company is operating very inefficient. -2
  • The TTM is -1,081.2%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-1,009.8%TTM-1,081.2%+71.4%
TTM-1,081.2%YOY-347.8%-733.4%
TTM-1,081.2%5Y-808.8%-272.4%
5Y-808.8%10Y-808.8%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1,009.8%-165.0%-844.8%
TTM-1,081.2%-237.4%-843.8%
YOY-347.8%-213.1%-134.7%
3Y-592.5%-267.2%-325.3%
5Y-808.8%-347.4%-461.4%
10Y-808.8%-509.4%-299.4%
4.3.2.2. Operating Ratio

Measures how efficient Lipella is keepingย operating costsย low.

  • Below 1 is considered healthy (always compare toย Biotechnology industry mean).
  • An Operation Ratio of 11.27 means that the operating costs are $11.27 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Lipella Pharmaceuticals Inc. Common Stock:

  • The MRQ is 11.270. The company is inefficient in keeping operating costs low. -1
  • The TTM is 10.412. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ11.270TTM10.412+0.857
TTM10.412YOY4.106+6.307
TTM10.4125Y10.424-0.011
5Y10.42410Y10.4240.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ11.2701.960+9.310
TTM10.4122.837+7.575
YOY4.1063.005+1.101
3Y6.1503.743+2.407
5Y10.4244.738+5.686
10Y10.4246.841+3.583
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Lipella Pharmaceuticals Inc. Common Stock.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Lipella is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toย Biotechnology industry mean).
  • A Current Ratio of 6.21ย means the company has $6.21 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Lipella Pharmaceuticals Inc. Common Stock:

  • The MRQ is 6.209. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.244. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ6.209TTM4.244+1.965
TTM4.244YOY7.623-3.379
TTM4.2445Y4.418-0.174
5Y4.41810Y4.4180.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.2093.467+2.742
TTM4.2443.689+0.555
YOY7.6234.099+3.524
3Y5.1284.658+0.470
5Y4.4185.739-1.321
10Y4.4186.151-1.733
4.4.3.2. Quick Ratio

Measures if Lipella is able to pay off Short-term Debt but only usingย theย most liquid assets.

  • Above 1 is considered healthy butย always compareย Lipella to theย Biotechnology industry mean.
  • A Quick Ratio of 5.55ย means the company can pay off $5.55 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Lipella Pharmaceuticals Inc. Common Stock:

  • The MRQ is 5.549. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 485.445. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ5.549TTM485.445-479.896
TTM485.445YOY6.893+478.552
TTM485.4455Y124.451+360.994
5Y124.45110Y124.4510.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.5492.994+2.555
TTM485.4453.326+482.119
YOY6.8933.908+2.985
3Y165.0534.438+160.615
5Y124.4515.809+118.642
10Y124.4516.537+117.914
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Lipella Pharmaceuticals Inc. Common Stock.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %ย of Lipellaย assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareย Lipella to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.16ย means that Lipella assets areย financed with 16.0% credit (debt) and the remaining percentage (100% - 16.0%)ย is financed by its owners/shareholders.ย 

Let's take a look of the Debt to Asset Ratio trends of Lipella Pharmaceuticals Inc. Common Stock:

  • The MRQ is 0.160. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.247. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.160TTM0.247-0.087
TTM0.247YOY0.157+0.090
TTM0.2475Y0.276-0.030
5Y0.27610Y0.2760.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1600.340-0.180
TTM0.2470.358-0.111
YOY0.1570.335-0.178
3Y0.3110.343-0.032
5Y0.2760.350-0.074
10Y0.2760.378-0.102
4.5.4.2. Debt to Equity Ratio

Measures ifย Lipella is able toย pay off its debts by usingย shareholders equity.

  • Below 2 is considered healthy butย always compareย Lipella to theย Biotechnology industry mean.
  • A Debt to Equity ratio of 19.0% means that company has $0.19 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Lipella Pharmaceuticals Inc. Common Stock:

  • The MRQ is 0.190. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.337. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.190TTM0.337-0.146
TTM0.337YOY0.189+0.147
TTM0.3375Y0.352-0.015
5Y0.35210Y0.3520.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1900.394-0.204
TTM0.3370.440-0.103
YOY0.1890.436-0.247
3Y0.3810.462-0.081
5Y0.3520.468-0.116
10Y0.3520.518-0.166
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measuresย how much money you payย for each share forย every $1 in earnings Lipella generates.

  • Above 15 is considered overpriced butย always compareย Lipella to theย Biotechnology industry mean.
  • A PE ratio of 0.00 means the investor is paying $0.00ย for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Lipella Pharmaceuticals Inc. Common Stock:

  • The EOD is 0.000. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.002. Based on the earnings, the company is expensive. -2
  • The TTM is -0.816. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD0.000MRQ-0.002+0.002
MRQ-0.002TTM-0.816+0.814
TTM-0.816YOY-1.279+0.462
TTM-0.8165Y-1.252+0.435
5Y-1.25210Y-1.2520.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.000-2.560+2.560
MRQ-0.002-2.297+2.295
TTM-0.816-2.662+1.846
YOY-1.279-3.749+2.470
3Y-1.669-3.773+2.104
5Y-1.252-6.353+5.101
10Y-1.252-7.043+5.791
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Lipella Pharmaceuticals Inc. Common Stock:

  • The EOD is 0.000. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.002. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.199. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD0.000MRQ-0.002+0.002
MRQ-0.002TTM-1.199+1.197
TTM-1.199YOY-1.664+0.465
TTM-1.1995Y-1.785+0.587
5Y-1.78510Y-1.7850.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.000-3.491+3.491
MRQ-0.002-3.099+3.097
TTM-1.199-3.812+2.613
YOY-1.664-4.274+2.610
3Y-2.381-5.149+2.768
5Y-1.785-8.383+6.598
10Y-1.785-9.373+7.588
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofย Lipella is to cheap or to expensiveย compared to its book value.

  • At or below 1 is considered healthyย (always compare to Biotechnology industry mean).
  • A PB ratio of 2.75 means the investor is paying $2.75ย for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Lipella Pharmaceuticals Inc. Common Stock:

  • The EOD is 0.624. Based on the equity, the company is cheap. +2
  • The MRQ is 2.749. Based on the equity, the company is underpriced. +1
  • The TTM is 3.118. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD0.624MRQ2.749-2.125
MRQ2.749TTM3.118-0.369
TTM3.118YOY2.180+0.938
TTM3.1185Y1.654+1.464
5Y1.65410Y1.6540.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.6242.315-1.691
MRQ2.7492.006+0.743
TTM3.1182.209+0.909
YOY2.1802.431-0.251
3Y2.2052.578-0.373
5Y1.6543.708-2.054
10Y1.6544.430-2.776
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Lipella Pharmaceuticals Inc. Common Stock.

4.8.1. Institutions holding Lipella Pharmaceuticals Inc. Common Stock

Institutions are holding 1.411% of the shares of Lipella Pharmaceuticals Inc. Common Stock.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31Tower Research Capital LLC0.06060.0002270827080
2025-03-31Mccormack Advisors International0.0028012500
2025-03-31Bank of America Corp0.00020700
2025-03-31Virtu Financial LLC000-13310-100
Total 0.06360.00022840-10602-373.3%

4.9.2. Funds holding Lipella Pharmaceuticals Inc. Common Stock

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-05-31Fidelity Extended Market Index0.12930577800
2025-05-31Vanguard Institutional Extnd Mkt Idx Tr0.09660431400
2025-05-31Fidelity Series Total Market Index0.030134100
Total 0.255901143300.0%

5.3. Insider Transactions

Insiders are holding 6.525% of the shares of Lipella Pharmaceuticals Inc. Common Stock.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-05-14Jonathan H KaufmanBUY12506.08
2024-03-18Jonathan H KaufmanBUY37506.32
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2024-03-312024-06-302024-09-302024-12-312025-03-31
Gross Profit  -843181-662-305-96678-889130,279129,390



5.2. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets4,856
Total Liabilities777
Total Stockholder Equity4,079
 As reported
Total Liabilities 777
Total Stockholder Equity+ 4,079
Total Assets = 4,856

Assets

Total Assets4,856
Total Current Assets4,823
Long-term Assets33
Total Current Assets
Cash And Cash Equivalents 4,225
Net Receivables 86
Other Current Assets 513
Total Current Assets  (as reported)4,823
Total Current Assets  (calculated)4,823
+/-0
Long-term Assets
Property Plant Equipment 33
Long-term Assets  (as reported)33
Long-term Assets  (calculated)33
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities777
Long-term Liabilities0
Total Stockholder Equity4,079
Total Current Liabilities
Short-term Debt 24
Accounts payable 392
Other Current Liabilities 361
Total Current Liabilities  (as reported)777
Total Current Liabilities  (calculated)777
+/-0
Long-term Liabilities
Long-term Liabilities Other 0
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock0
Retained Earnings -16,647
Other Stockholders Equity 20,726
Total Stockholder Equity (as reported)4,079
Total Stockholder Equity (calculated)4,079
+/- 0
Other
Capital Stock0
Cash and Short Term Investments 4,225
Common Stock Shares Outstanding 1,048
Liabilities and Stockholders Equity 4,856
Net Debt -4,201
Net Invested Capital 4,079
Net Working Capital 4,046
Property Plant and Equipment Gross 164
Short Long Term Debt Total 24



5.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-31
> Total Assets 
0
0
0
2,013
1,517
1,051
874
5,950
4,615
3,490
2,841
3,577
3,137
2,184
2,160
2,674
4,856
4,8562,6742,1602,1843,1373,5772,8413,4904,6155,9508741,0511,5172,013000
   > Total Current Assets 
607
0
0
1,808
1,330
873
709
5,799
4,478
3,367
2,671
3,429
3,011
2,081
2,080
2,617
4,823
4,8232,6172,0802,0813,0113,4292,6713,3674,4785,7997098731,3301,80800607
       Cash And Cash Equivalents 
-607
0
0
1,414
414
435
115
5,122
4,019
3,114
2,410
3,294
2,105
1,187
1,354
2,185
4,225
4,2252,1851,3541,1872,1053,2942,4103,1144,0195,1221154354141,41400-607
       Short-term Investments 
1,213
0
0
301
601
0
0
0
0
0
0
0
0
0
1,352,380
0
0
001,352,380000000000601301001,213
       Net Receivables 
0
0
0
0
0
0
0
114
84
28
53
32
69
35
31
85
86
8685313569325328841140000000
       Other Current Assets 
0
0
0
94
315
438
594
564
375
225
208
103
837
859
726
348
513
51334872685983710320822537556459443831594000
   > Long-term Assets 
-607
0
0
205
187
178
165
151
137
123
170
148
126
103
80
57
33
33578010312614817012313715116517818720500-607
       Property Plant Equipment 
0
0
0
205
187
178
165
151
137
123
170
148
126
103
80
57
33
335780103126148170123137151165178187205000
       Long-term Assets Other 
-607
0
0
0
0
-178
-165
-151
-137
-123
13,472
0
12,029
0
80,060
0
9,142
9,142080,060012,029013,472-123-137-151-165-1780000-607
> Total Liabilities 
0
0
0
589
596
699
937
1,275
798
364
619
433
576
480
701
754
777
7777547014805764336193647981,275937699596589000
   > Total Current Liabilities 
0
0
0
341
346
448
742
1,178
717
299
549
385
552
480
701
754
777
7777547014805523855492997171,178742448346341000
       Short-term Debt 
0
0
0
65
47
39
82
333
310
61
87
89
92
94
71
48
24
244871949289876131033382394765000
       Short Long Term Debt 
0
0
0
25
25
25
25
275
250
0
0
0
0
0
0
0
0
0000000025027525252525000
       Accounts payable 
0
0
0
47
56
55
352
384
149
22
303
138
294
178
459
388
392
39238845917829413830322149384352555647000
       Other Current Liabilities 
0
0
0
-129
242
354
307
461
259
216
158
158
166
208
171
319
361
361319171208166158158216259461307354242-129000
   > Long-term Liabilities 
0
0
0
249
250
251
195
96
81
65
70
47
24
0
0
0
0
0000244770658196195251250249000
       Other Liabilities 
0
0
0
0
0
0
34
0
0
0
0
0
0
0
0
0
0
000000000034000000
> Total Stockholder Equity
463
0
0
1,424
921
352
-63
4,676
3,816
3,125
2,222
3,144
2,561
1,704
1,459
1,919
4,079
4,0791,9191,4591,7042,5613,1442,2223,1253,8164,676-633529211,42400463
   Common Stock
0
0
0
1
1
1
1
1
1
1
1
1
1
1
0
0
0
00011111111111000
   Retained Earnings Total Equity00000000000000000
   Accumulated Other Comprehensive Income 
463
0
0
-3,107
-3,845
0
0
0
0
0
0
0
0
0
0
0
0
000000000000-3,845-3,10700463
   Capital Surplus 00000000000000000
   Treasury Stock00000000000000000
   Other Stockholders Equity 
0
0
0
4,530
4,765
4,978
5,277
10,380
10,589
11,436
11,856
13,468
14,076
14,157
15,357
17,259
20,726
20,72617,25915,35714,15714,07613,46811,85611,43610,58910,3805,2774,9784,7654,530000



5.4. Balance Sheets

Currency in USD. All numbers in thousands.




5.5. Cash Flows

Currency in USD. All numbers in thousands.




5.6. Income Statements

Currency in USD. All numbers in thousands.


5.7. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue536
Cost of Revenue-3,613
Gross Profit-3,077-3,077
 
Operating Income (+$)
Gross Profit-3,077
Operating Expense-5,614
Operating Income-5,081-8,691
 
Operating Expense (+$)
Research Development3,613
Selling General Administrative2,004
Selling And Marketing Expenses0
Operating Expense5,6145,617
 
Net Interest Income (+$)
Interest Income64
Interest Expense-0
Other Finance Cost-0
Net Interest Income64
 
Pretax Income (+$)
Operating Income-5,081
Net Interest Income64
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-5,016-5,145
EBIT - interestExpense = -5,016
-5,021,280
-5,016
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-5,016-5,016
Earnings Before Interest and Taxes (EBITDA)-5,013
 
After tax Income (+$)
Income Before Tax-5,016
Tax Provision-0
Net Income From Continuing Ops-5,016-5,016
Net Income-5,016
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses5,617
Total Other Income/Expenses Net64-64
 

Technical Analysis of Lipella
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Lipella. The general trend of Lipella is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Lipella's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Lipella Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Supportย is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistanceย is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Lipella Pharmaceuticals Inc. Common Stock.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 0.64 < 0.641 < 0.641.

The bearish price targets are: 0.57 > 0.55.

Know someone who trades $LIPO? Share this with them.๐Ÿ‘‡

Lipella Pharmaceuticals Inc. Common Stock Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theย moving averageย of the selected period.

  • Moving averages are laggingย trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Lipella Pharmaceuticals Inc. Common Stock. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Lipella Pharmaceuticals Inc. Common Stock Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theย momentumย of theย selected period based on two moving averages.

  • MACD is aย lagging momentumย indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Lipella Pharmaceuticals Inc. Common Stock.

Lipella Pharmaceuticals Inc. Common Stock Daily Moving Average Convergence/Divergence (MACD) ChartLipella Pharmaceuticals Inc. Common Stock Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Lipella Pharmaceuticals Inc. Common Stock. The current adx is .

Lipella Pharmaceuticals Inc. Common Stock Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Showsย the current trend.
  • Showsย potential entry signals.
  • Showsย ย potential exit signals.
  • Can be used to placeย trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Lipella Pharmaceuticals Inc. Common Stock.

Lipella Pharmaceuticals Inc. Common Stock Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumย indicator, meaning the signals are instant.
  • Rangesย between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Lipella Pharmaceuticals Inc. Common Stock.

Lipella Pharmaceuticals Inc. Common Stock Daily Relative Strength Index (RSI) ChartLipella Pharmaceuticals Inc. Common Stock Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Comparesย a certain price to multiple prices ranging over time.

  • Leadingย momentumย indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Rangesย between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Lipella Pharmaceuticals Inc. Common Stock.

Lipella Pharmaceuticals Inc. Common Stock Daily Stochastic Oscillator ChartLipella Pharmaceuticals Inc. Common Stock Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,ย the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Lipella Pharmaceuticals Inc. Common Stock.

Lipella Pharmaceuticals Inc. Common Stock Daily Commodity Channel Index (CCI) ChartLipella Pharmaceuticals Inc. Common Stock Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Lipella Pharmaceuticals Inc. Common Stock.

Lipella Pharmaceuticals Inc. Common Stock Daily Chande Momentum Oscillator (CMO) ChartLipella Pharmaceuticals Inc. Common Stock Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

ย Shows the current price relative to the highest high over the last 14 days.
ย 

  • Lagging momentum indicator
  • Ranging between 0 andย -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Lipella Pharmaceuticals Inc. Common Stock.

Lipella Pharmaceuticals Inc. Common Stock Daily Williams %R ChartLipella Pharmaceuticals Inc. Common Stock Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldย 

Score

Let's take a look at the Bollinger Bands of Lipella Pharmaceuticals Inc. Common Stock.

Lipella Pharmaceuticals Inc. Common Stock Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Lipella Pharmaceuticals Inc. Common Stock.

Lipella Pharmaceuticals Inc. Common Stock Daily Average True Range (ATR) ChartLipella Pharmaceuticals Inc. Common Stock Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

ย Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Lipella Pharmaceuticals Inc. Common Stock.

Lipella Pharmaceuticals Inc. Common Stock Daily On-Balance Volume (OBV) ChartLipella Pharmaceuticals Inc. Common Stock Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Lipella Pharmaceuticals Inc. Common Stock.

Lipella Pharmaceuticals Inc. Common Stock Daily Money Flow Index (MFI) ChartLipella Pharmaceuticals Inc. Common Stock Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Lipella Pharmaceuticals Inc. Common Stock.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-04-22STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-24SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-25CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-04-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-29CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-30CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-01STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-06STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-09MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-05-14WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-15SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-05-16MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-05-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-22STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-28STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-29WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-30STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-05WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-06STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-10MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-06-11CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-06-16DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-17STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-20ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-23STOCH SHORT EXITThe %K line crosses above the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-24STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-06-25STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-30STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-07STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-08STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-10STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-07-15MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-07-16STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-07-18STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-21SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2025-07-22STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-07-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-25SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-07-28RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-31STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-01STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-04STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-08-05WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-08-07STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-08-08STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-08-11RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-08-18STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-19CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-08-20STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-22STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-25STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-27SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-08-28STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-09-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-09-03STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Lipella Pharmaceuticals Inc. Common Stock Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Lipella Pharmaceuticals Inc. Common Stock based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose0.591
Total1/1 (100.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Lipella with someone you think should read this too:
  • Are you bullish or bearish on Lipella? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Lipella? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Lipella Pharmaceuticals Inc. Common Stock

I send you an email if I find something interesting about Lipella Pharmaceuticals Inc. Common Stock.


Comments

How you think about this?

Leave a comment

Stay informed about Lipella Pharmaceuticals Inc. Common Stock.

Receive notifications about Lipella Pharmaceuticals Inc. Common Stock in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.